8 Sources of evidence considered by the committee
A. The assessment report for this appraisal was prepared by Kleijnen Systematic Reviews:
Riemsma R, Ramaekers B, Tomini F et al. (2014) Abiraterone for the treatment of chemotherapy naive metastatic castration-resistant prostate cancer.
B. The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, assessment report and the appraisal consultation document. Organisations listed in I were also invited to make written submissions. Organisations listed in II and III had the opportunity to make written submissions. Organisations listed in I, II and III also have the opportunity to appeal against the final appraisal determination.
I. Companies/sponsors:
Janssen
II. Professional/specialist and patient/carer groups:
-
British Association of Urological Surgeons
-
British Uro-Oncology Group
-
Cancer Research UK
-
Prostate Cancer UK
-
Royal College of Nursing
-
Royal College of Physicians
-
Tackle Prostate Cancer
The Urology Foundation
III. Other consultees:
-
Department of Health
-
NHS England
Welsh Government
IV. Commentator organisations (did not provide written evidence and without the right of appeal):
-
Commissioning Support Appraisals Service
-
Department of Health, Social Services and Public Safety for Northern Ireland
-
Healthcare Improvement Scotland
-
National Collaborating Centre for Cancer
Sanofi
C. The following individuals were selected from clinical and patient expert nominations from the consultees and commentators. They gave their expert personal view on abiraterone by attending the initial committee discussion and providing a written statement to the committee. They are invited to comment on the appraisal consultation document.
-
Dr John Graham, Consultant Clinical Oncologist and Director, National Collaborating Centre for Cancer, nominated by the National Collaborating Centre for Cancer – clinical specialist
-
Dr Simon Hughes, Consultant Clinical Oncologist, Guy's and St Thomas' NHS Trust, nominated by the British Uro-oncology Group – clinical specialist
-
David Smith, Hon. Secretary, Tackle Prostate Cancer, nominated by Tackle Prostate Cancer – patient expert
Stuart Watson, volunteer, Prostate Cancer UK, nominated by Prostate Cancer UK – patient expert
D. Representatives from the following companies/sponsors attended committee meetings. They contributed only when asked by the committee chair to clarify specific issues and comment on factual accuracy.
Janssen
Update information
July 2016: This guidance was re-issued after a change to the commercial arrangements in July 2016. It was verified that this change did not impact cost effectiveness. Recommendation 1.1, sections 2.3 and 5.4, and the summary of appraisal committee key conclusions table have been updated.